THIS ISSUE HAS NO PART II (REVISED REGULATIONS) or PART III (REGULATIONS)/
CE NUMÉRO NE CONTIENT PAS DE PARTIE II (RÈGLEMENTS RÉVISÉS) OU DE PARTIE III (RÈGLEMENTS)

The Saskatchewan Gazette

PUBLISHED WEEKLY BY AUTHORITY OF THE KING'S PRINTER/PUBLIÉE CHAQUE SEMAINE SOUS L'AUTORITÉ DE L'IMPRIMEUR DU ROI

PART I/PARTIE I

Volume 119 | REGINA, FRIDAY, JULY 28, 2023/REGINA, vendredi 28 juillet 2023 | No. 30/nº30

TABLE OF CONTENTS/TABLE DES MATIÈRES

PART I/PARTIE I

SPECIAL DAY/JOUR SPÉCIAL

The following day has been designated by the Minister of Health as:

"World Hepatitis Day" in Saskatchewan, July 28, 2023.

ACTS NOT YET IN FORCE/LOIS NON ENCORE EN VIGUEUR

Title/ Titre:	Chapter/ Chapitre:
The Aboriginal Courtworkers Commission Act, S.S. 1995 Assented to May 18, 1995	A-1.1
The Accessible Saskatchewan Act Assented to May 17, 2023	19
The Alcohol and Gaming Regulation Amendment Act, 2023, S.S. 2023 Assented to April 25, 2023, sections 12, 13, 15, 16, 20 and 28; and clause 31(a) not yet in force	14
The Animal Production Act, 2022, S.S. 2022 Assented to May 18, 2022	2
The Apiaries Amendment Act, 2020, S.S. 2020 Assented to July 3, 2020	18
The Automobile Accident Insurance (Miscellaneous) Amendment Act, 2023, S.S. 2023 Assented to April 6, 2023, sections 3, 8, 9, 18, 19, 21 and 25 not yet in force	2
The Business Corporations Act, 2021, S.S. 2021 Assented to May 13, 2021, subsection 7-2(5) not yet proclaimed	6
The Cannabis Control (Saskatchewan) Amendment Act, 2023, S.S. 2023 Assented to May 17, 2023, sections 1 to 5 and 7 to 37 not yet proclaimed	22
The Child and Family Services Amendment Act, 2023, S.S. 2023 Assented to April 25, 2023	15
The Consumer Protection and Business Practices Act, S.S. 2013 Assented to May 15, 2013, sections 114 to 116 and 118 to 119; subsections 121(2) and 122(3) to (5), (7) and (8) not yet proclaimed	C-30.2
The Credit Union Act, 1998, S.S. 1998 Assented to June 11, 1998, clauses 2(1)(v), subsection 9(2), clause 10(c), Parts VI and XXI, clauses 440(1)(o) to (s) and (hh), and subsection 440(2) not yet proclaimed	C-45.2
The Credit Union Amendment Act, 2010, S.S. 2010 Assented to May 20, 2010, clause 3(b) not yet proclaimed	8
The Data Matching Agreements Act, S.S. 2018 Assented to May 9, 2018	D-1.3
The Dental Disciplines Amendment Act, 2022, S.S. 2022 Assented to May 18, 2022	6
The Doukhobors of Canada C.C.U.B. Trust Fund Amendment and Repeal Act, 2021, S.S. 2021 Assented to May 13, 2021, section 6 not yet in force	11

Title/ Titre:	Chapter/ Chapitre:

Title/ Titre:	Chapter/ Chapitre:

Title/ Titre:	Chapter/ Chapitre:

Title/ Titre:	Chapter/ Chapitre:
The Surface Rights Acquisition and Compensation Amendment Act, 2023, S.S. 2023 Assented to April 6, 2023	11
The Traffic Safety Amendment Act, 2020, S.S. 2020 Assented to July 3, 2020, section 10; and clause 35(b) not yet in force	36
The Traffic Safety Amendment Act, 2022, S.S 2022 Assented to May 18, 2022, section 6 not yet proclaimed	44
The Traffic Safety (Miscellaneous) Amendment Act, 2021, S.S. 2021 Assented to May 13, 2021, clause 3(a), sections 6, 9 and 10, clauses 13(a), sections 15 to 23, 25, 27, 35 to 37 not yet proclaimed	32
The Traffic Safety (Miscellaneous) Amendment Act, 2023, S.S. 2023 Assented to April 6, 2023, section 4 not yet in force	13
The Trust and Loan Corporations Act, 1997, S.S. 1997 Assented to May 21, 1997, clause 44(a) and section 57 not yet proclaimed	T-22.2
The Vehicles for Hire Amendment Act, 2021, S.S. 2021 Assented to May 13, 2021	34
The Victims of Crime Amendment Act, 2011, S.S. 2011/ Loi de 2011 modifiant la Loi de 1995 sur les victimes d'actes criminels, L.S. 2011 Assented to May 18, 2011	21
The Warrant Compliance Act, S.S. 2023 Assented to May 17, 2023	44
The Wills Amendment Act, 2023, S.S. 2023/Loi modificative de 2023 sur les testaments, L.S. 2023 Assented to May 17, 2023	45

***Note:** This table is for convenience of reference and is not comprehensive; it is meant to be used in conjunction with the *Legislative Table of Public Statutes* published by the Office of the King's Printer. Please refer to the Separate Chapters and the Tables for any additional information regarding Proclamation dates and Coming into Force dates for the Statutes listed above./Le présent tableau a pour but de faciliter la référence et n'est pas complet; il est utilisé en conjonction avec le Tableau des lois de la Saskatchewan (*Legislative Table of Public Statutes)* publié par le bureau de l'Imprimeur du Roi. Veuillez vous référer aux chapitres tirés à part et au Tableau pour obtenir de plus amples renseignements relatifs aux dates de proclamation et d'entrée en vigueur des lois susmentionnées.

ACTS IN FORCE ON ASSENT/LOIS ENTRANT EN VIGUEUR SUR SANCTION

(Third Session, Twenty-Ninth Legislative Assembly/Troisième session session, 29e Assemblée législative)

Title/ Titre:	Bill/ Projet de loi:	Chapter/ Chapitre:
The Appropriation Act, 2023 (No. 1) (Assented to May 17, 2023)	136	20
The Appropriation Act, 2022 (No. 2) (Assented to December 6, 2022)	127	47
The Architects Amendment Act, 2023 (Assented to April 6, 2023)	97	1
The Automobile Accident Insurance (Miscellaneous) Amendment Act, 2023 (Assented to April 6, 2023), sections 1, 2, 4 to 7, 10 to 17, 20, 22 to 24 and 26	92	2

Title/ Titre:	Bill/ Projet de loi:	Chapter/ Chapitre:
The Boiler and Pressure Vessel (Automation and Remote Supervision Pilot) Amendment Act, 2023 (Assented to May 17, 2023)	132	21
The Constitutional Questions Amendment Act, 2023/Loi modificative de 2023 sur les questions constitutionnelles (Assented to April 6, 2023)	102	3
The Election Amendment Act, 2022 (Assented to December 7, 2022)	123	49
The Income Tax (Affordability) Amendment Act, 2022 (Assented to November 14, 2022)	89	46
The Income Tax Amendment Act, 2023 (Assented to May 17, 2023)	133	27
The King's Bench Act/Loi sur la Cour du Banc du Roi (Assented to May 17, 2023)	114	28
The King's Counsel Act (Assented to May 17, 2023)	115	29
The King's Printer Act (Assented to May 17, 2023)	112	30
The Leafcutting Beekeepers Registration Repeal Act (Assented to April 6, 2023)	96	4
The Lotteries and Gaming Corporation Act, 2023 (Assented to May 17, 2023)	130	34
The Mineral Resources Amendment Act, 2023 (Assented to May 17, 2023)	128	37
The Saskatcewan Employment (Part III) Amendment Act, 2023 (Assented to May 17, 2023), sections 1 to 6 and 8 to 22	91	40
The Telecommunications Statutes (Borrowing Powers) Amendment Act, 2023 (Assented to April 6, 2023)	90	12
The Traffic Safety (Miscellaneous) Amendment Act, 2023 (Assented to April 6, 2023), sections 1 to 3 and 5 to 7	93	13
The Trespass to Property Amendment Act, 2023 (Assented to May 17, 2023)	109	43

ACTS IN FORCE ON SPECIFIC DATES/LOIS EN VIGUEUR À DES DATES PRÉCISES

Title/ Titre:	Bill/ Projet de loi:	Chapter/ Chapitre:
The Education Amendment Act, 2023/Loi modicative de 2023 sur l'éducation (Assented to May 17, 2023), section 82 in force August 31, 2024	134	23
The Local Election Amendment Act, 2023 (Assented to May 17, 2023), in force January 1, 2024	105	32

Title/ Titre:	Bill/ Projet de loi:	Chapter/ Chapitre:
The Local Improvements Amendment Act, 2023 (Assented to May 17, 2023), in force January 1, 2024	104	33
The Saskatchewan Employment (Part III) Amendment Act, 2023 (Assented to May 17, 2023), section 7 in force May 18, 2024	91	40
The Statute Law Amendment Act, 2015, S.S. 2015 (Assented to May 14, 2015), subsection 64(3) and Schedule 3 come into force on the coming into force of Part XXI of *The Credit Union Act, 1998*	153	21
The Summary Offences Procedure Amendment Act, 2017, S.S. 2017 (Assented to May 17, 2017), sections 1 to 3 and 5 not yet proclaimed; section 4 comes into force on the day on which sections 5 and 11 of *The Summary Offences Procedure Amendment Act, 2016* come into force	59	26

ACTS IN FORCE ON SPECIFIC EVENTS/ LOIS ENTRANT EN VIGUEUR À DES OCCURRENCES PARTICULIÈRES

Title/ Titre:	Chapter/ Chapitre:
The Education Consequential Amendments Act, 2023 (Assented to May 17, 2023) Specific Event: comes into force on the day on which section 1 of *The Education Amendment Act, 2023* comes into force	24
The King's Printer Consequential Amendments Act, 2023/ Loi de 2023 corrélative de la loi intitulée The King's Printer Act (Assented to May 17, 2023) Specific Event: comes into force on the day on which section 1 of *The King's Printer Act* comes into force	31
The Representation Act, 2022, S.S 2022 (Assented to December 6, 2022) Specific Event: comes into force on the day after the day on which the Twenty-Ninth Legislative Assembly is dissolved or is determined by effluxion of time	48
The Reviewable Transactions Consequential Amendments Act, 2022, S.S 2022/ Loi de 2022 corrélative de la loi intitulée The Reviewable Transactions Act, L.S. 2022 (Assented to May 18, 2022) Specific Event: comes into force on the coming into force of section 1 of *The Reviewable Transactions Act*	35
The Summary Offences Procedure Amendment Act, 2023 (Assented to May 17, 2023) Specific Event: if section 12 of *The Summary Offences Procedure Amendment Act, 2021* comes into force after the date on which this Act comes into force, section 10 of this Act comes into force on the date on which section 12 of *The Summary Offences Procedure Amendment Act, 2021* comes into force; if section 18 of *The Summary Offences Procedure Amendment Act, 2021* comes into force after the date on which this Act comes into force, section 11 of this Act comes into force on the date on which section 18 of *The Summary Offences Procedure Amendment Act, 2021* comes into force	42

ACTS IN FORCE BY ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL/LOIS EN VIGUEUR PAR DÉCRET DU LIEUTENANT-GOUVERNEUR EN CONSEIL

(2023)

Title/ Titre:	Bill/ Projet de loi:	Chapter/ Chapitre:
The Alcohol and Gaming Regulation Amendment Act, 2023, S.S. 2023 Assented to April 25, 2023, sections 1 to 11, 14, 17 to 19, 21 to 27, 29 to 30, clauses 31(b) to (f) and section 32, in force May 23, 2023	124	14
The Business Corporations Act, 2021, S.S. 2021 Assented to May 13, 2021, sections 1-1 to 7-1; subsections 7-2(1) to (4) and (6) to (16); and sections 7-3 to 23-27, in force March 12, 2023	5	6
The Cannabis Control (Saskatchewan) Amendment Act, 2023, S.S. 2023 Assented to May 17, 2023, section 6, in force June 5, 2023	125	22
The Emergency 911 System Amendment Act, 2023, S.S. 2023 Assented to May 17, 2023, in force July 1, 2023	99	25
The Health Shared Services Saskatchewan (3sHealth) Act, 2022, S.S 2022 Assented to May 18, 2022, in force April 1, 2023	45	9
The Insurance Amendment Act, 2022, S.S. 2022 Assented to May 18, 2022, in force May 1, 2023	71	13
The Justices of the Peace Amendment Act, 2022, S.S. 2022/Loi modificative de 2022 sur les juges de paix, L.S. 2022 Assented to May 18, 2022, in force May 5, 2023	59	15
The Legal Aid Amendment Act, 2022, S.S. 2022 Assented to May 18, 2022, in force February 1, 2023	46	18
The Medical Profession Amendment Act, 2023, S.S. 2023 Assented to May 17, 2023, in force June 30, 2023	129	36
The Miscellaneous Statutes (Health Professions) Amendment Act, 2023, S.S. 2023 Assented to April 6, 2023, section 1-1 to subsection 7-17(1); sections 9-1 to 9-13; sections 11-1 to 25-1, in force May 15, 2023	120	6
The Non-profit Corporations Act, 2022, S.S. 2022/Loi de 2022 sur les organisations sans but lucratif, L.S. 2022 Assented to May 18, 2022, sections 1-1 to 6-3; subsections 6-4(1) to (4) and (6) to (14); and sections 6-15 to 22-9, in force March 12, 2023	75	25
The Police Amendment Act, 2023, S.S. 2023 Assented to April 25, 2023, in force April 28, 2023	106	17
The Police (Serious Incident Response Team) Amendment Act, 2021, S.S. 2021 Assented to May 13, 2021, in force January 1, 2023	26	22
The Provincial Protective Services Act, S.S. 2023 Assented to April 6, 2023, in force May 5, 2023	107	7
The Saskatchewan Firearms Act, S.S. 2023 Assented to April 6, 2023, sections 1-1 to 3-16; subsections 3-17(1) to (4); clause 3-17(5)(b); subsections 3-17(6) and (7); section 3-19; subsection 4-1(1); clauses 4-1(2)(c) and (e); subsection 4-1(3); sections 4-2 to 5-1; subsections 5-6(1) to (7); sections 5-7; sections 5-9 and 5-12; sections 6-1 to 6-8; clauses 6-9(a) to (d), (f) to (i) and (k) to (m); and section 6-10, in force May 19, 2023	117	8

Title/ Titre:	Bill/ Projet de loi:	Chapter/ Chapitre:
The Summary Offences Procedure Amendment Act, 2021, S.S. 2021 Assented to May 13, 2021, sections 12 and 18 in force April 1, 2023	27	30

***Note:** An order appearing in this list for the first time is indicated in bold print/Un décret qui figure pour la première fois dans cette liste apparaît en caractères gras.

ACTS PROCLAIMED/LOIS PROCLAMÉES

(2023)

The Health Information Protection Act, S.S. 1999. Subsections 17(1), 18(2) and 18(4) proclaimed in force August 1, 2023.

The Residential Services Act, 2019, S.S. 2019, c.R-21.3. Proclaimed in force January 1, 2023.

***Note:** A proclamation appearing in this list for the first time is indicated in bold print/Une loi proclamée qui figure pour la première fois dans cette liste apparaît en caractères gras.

MINISTER'S ORDER/ARRETE MINISTERIEL

The Regional Parks Act, 2013

[*clause 21(1)(b)*]

I, Laura Ross, Minister of Parks, Culture and Sport, pursuant to clause 21(1)(b) of *The Regional Parks Act, 2013* and with the approval of the Lieutenant Governor in Council as per Order in Council 344/2023, being satisfied that it is in the public interest to do so, hereby order that the Oyama Regional Park Authority, as originally established by Order in Council 1456/61, is hereby dissolved as a regional park authority.

This order is required to complete the request made by the Oyama Regional Park Authority that it be dissolved.

Dated at Regina, Saskatchewan, this 17th day of July, 2023.

Laura Ross,
Minister of Parks, Culture and Sport.

PUBLIC NOTICES/AVIS PUBLIC

The Change of Name Act, 1995/Loi de 1995 sur le changement de nom

The following changes of name are registered under the provisions of *The Change of Name Act, 1995*/ Les changements de nom ci-après sont enregistrés en exécution de la *Loi de 1995 sur le changement de nom:*

Former Name/ Ancien nom:	Address/ Addresse:	Date of Birth/ Date de naissance:	Name Changed To/ Nouveau nom:
Malcolm Graham Leighton Grant WHYTE (Dated July 14, 2023)	Saskatoon SK	March 28, 1981	Malcolm Graham WHYTE

Former Name/ Ancien nom:	**Address/ Addresse:**	**Date of Birth/ Date de naissance:**	**Name Changed To/ Nouveau nom:**
Rudy Jamey CARIBOU-DAYLIGHT (Dated July 17, 2023)	Sandy Bay SK	April 19, 1997	Ethan Jamey STEWART
Lokpriy LOKPRIY (Dated July 18, 2023)	Saskatoon SK	December 4, 1977	Lokpriy SHRMA
Lanna Jean SWAIN (Dated July 18, 2023)	Yorkton SK	January 14, 1998	Cyrus Jean SWAIN
Muriel Helen TADEI (Dated July 18, 2023)	Rosthern SK	December 7, 1945	Murial Helen TADEI
Rebecca Carmela TOMLIN (Dated July 18, 2023)	Saskatoon SK	December 8, 1995	Rebecca Carmelia TOEWS
Jhanvi Mukesh DAVE (Dated July 18, 2023)	Regina SK	January 24, 1993	Jhanvi Krutarth VYAS
Jinky Duldulao SIGUA (Dated July 18, 2023)	Saskatoon SK	September 6, 1988	Jinky Sigua WAGNER
Tracey Dawn SCHUBERT (Dated July 18, 2023)	Regina SK	January 7, 1971	Trace YELLOWTAIL

Name(s) of Child or Children/Nom(s) de l'enfant ou des enfants:		
Former Name/ Ancien nom:	**Date of Birth/ Date de naissance:**	**Name Changed To/ Nouveau nom:**
Lochlan Hugh ROBERTS (Dated July 18, 2023)	November 14, 2007	Lilly ROBERTS

Given under my hand at the City of Regina, in the Province of Saskatchewan/Fait sous ma signature dans la ville de Regina, dans la province de la Saskatchewan.

Jennifer Lindenbach,
Registrar of Vital Statistics/
Registraire des Services de l'état Civil.

The Election Act, 1996
[*clause 233(b)*]

PUBLICATION OF INFORMATION

Pursuant to clause 233(b) of *The Election Act, 1996*, notice is hereby given that the Registered Political Party previously known as the Saskatchewan Liberal Party (Sask Liberals) is now known as the Saskatchewan Progress Party (Sask Progress), effective July 19, 2023.

Michael D. Boda, D.Phil., Ph.D.,
Chief Electoral Officer.

The Highways and Transportation Act, 1997
[*section 20.1]*

ESTABLISHMENT OF A SPEED ZONE – PROVINCIAL HIGHWAY NO. 44

NOTICE IS HEREBY GIVEN that, effective immediately, pursuant to section 20.1 of *The Highways and Transportation Act, 1997*, the Minister establishes a speed zone under Schedule B by erecting official signs stating the speed limit at the following location:

- 80 km/hr on Provincial Highway No. 44 from a point 200 m east of its junction with Public Highway No. 664 to a point 200 m east of its junction with 4th St. W in the Village of Wiseton SK.

Dated at Regina, Saskatchewan, the 19th day of July, 2023.

Tom Lees,
Assistant Deputy Minister,
Operation and Maintenance Division,
Ministry of Highways.

The Municipalities Act
[*section 214*]

NOTICES OF PREPARATION OF ASSESSMENT ROLLS
(2023)

URBAN MUNICIPALITIES

Village of Denholm

Notice is hereby given that the assessment roll for the Village of Denholm for the year 2023 has been prepared and is open to inspection by calling 306-480-6206, July 28 to August 28, 2023.

A bylaw pursuant to section 214 of *The Municipalities Act* has been passed and the assessment notices have been sent as required.

Any person wishing to discuss the notice of assessment or potential appeal may contact the assessor at the Village of Denholm, Box 71, Denholm SK S0M 0R0. A notice of appeal must be filed with the Secretary of the Board of Revision, Marlene Hassard, Western Municipal Consulting Ltd., Box 149, Meota SK S0M 1X0, by the 28th day of August, 2023.

Dated this 28th day of July, 2023.

R. Denise Porter,
Assessor.

Village of Dubuc

Notice is hereby given that the assessment roll for the Village of Dubuc for the year 2023 has been prepared and is open to inspection in the office of the assessor from 9 a.m. to noon and from 1 to 3 p.m. on Wednesdays and Thursdays, July 28 to August 18, 2023.

A bylaw pursuant to section 214 of *The Municipalities Act* has been passed and the assessment notices have been sent as required.

Any person wishing to discuss the notice of assessment or potential appeal may contact the assessor at the Village of Dubuc, Box 126, Dubuc SK S0A 0R0. A notice of appeal, accompanied by a $75 appeal fee which will be returned if the appeal is successful, must be filed with the Secretary of the Board of Revision, Marlene Hassard, Western Municipal Consulting Ltd., Box 149, Meota SK S0M 1X0, by the 18th day of August, 2023.

Dated this 28th day of July, 2023.

Village of Dubuc,
Assessor.

The Operation of Public Registry Statutes Act

[*subsection 15(1)*]

REGISTRAR OF TITLES' ORDER – SUSPENSION OF REGISTRY SERVICES AND FUNCTIONS

Whereas subsection 15(1) of *The Operation of Public Registry Statutes Act* reads as follows:

> **"15**(1) Notwithstanding any other Act or law, if, in the opinion of a registry officer or the minister, the circumstances are such that it is not practical to provide one or more registry services or functions, a registry officer or the minister may, by order, suspend all or any registry services or functions for the period during which, in the opinion of the registry officer or the minister, those circumstances prevail**".**

And whereas the Land Registry services and functions are provided to the public by Information Services Corporation.

And whereas Information Services Corporation will be making changes to the IT systems used for the purposes of registration and search services in the Land Registry commencing July 29, 2023.

And whereas for the purposes of completing these technical changes it is necessary to complete examination of all pending registration submissions, clearing the registration queue, before these technical changes may be made.

Therefore, I, Karen Banks, Registrar of Titles, do hereby direct that effective 3 p.m. on Friday, July 28, 2023, acceptance of applications for registration will be suspended until such time as the technical changes are concluded or until 11:59 p.m. Sunday, July 30, 2023, whichever occurs first.

Notice of this order shall be published in the *The Saskatchewan Gazette* and by posting to www.isc.ca.

CERTIFIED TRUE COPY:

Karen Banks,
Registrar of Titles.
Date: July 11, 2023.

The Pharmacy and Pharmacy Disciplines Act
[*clauses 14(2)(a) and (a.1), subclause 14(a.1)(i) and subsection 15(1)*]

SASKATCHEWAN COLLEGE OF PHARMACY PROFESSIONALS —
REGULATORY BYLAW AMENDMENTS

Under the authority of clauses 14(2)(a), (a.1), subclause 14(a.1)(i), and in accordance with subsection 15(1) of *The Pharmacy and Pharmacy Disciplines Act*, the Regulatory Bylaws of the Saskatchewan College of Pharmacy Professionals are amended as follows:

(1) That PART K – PRESCRIBING OF DRUGS be repealed and replaced with the following:

"PART K – PRESCRIBING OF DRUGS

Definitions

1 In this Part:

(a) **"Collaborative Practice Agreement"** means either:

(i) a voluntary written and signed agreement between one or more licensed pharmacists and one or more practitioners who have agreed to work together under protocol, in a Collaborative Practice Environment, to provide patient care and drug therapy management services and that outlines who may perform certain patient care functions under certain specified conditions or limitations authorized by the practitioner and by Council; or

(ii) a written bylaw, policy, clinical standard of a Public Health Care Institution, or agreement between one or more licensed pharmacists and a Public Health Care Institution, that outlines patient care and drug therapy management functions performed by licensed pharmacists and other health care providers employed by, or practising in the Public Health Care Institution, which includes the conditions or limitations authorized by the Public Health Care Institution and by Council;

(b) **"Collaborative Practice Environment"** means a deliberate and committed professional approach to communication, decision-making, and shared knowledge and skills that health care providers can reasonably rely upon to provide safe patient care, including the referral to practitioner(s) or other health care providers as appropriate;

(c) **"De-prescribe"** means the planned and supervised process of reducing or stopping a drug;

(d) **"Dosage amount"** or **"Dose"** means a specific amount or strength of drug prescribed or directed to be taken;

(e) **"Dosage form"** means the physical formulation, including release profile, in which the drug is manufactured and made available for use;

(f) **"Dosage regimen"** means the frequency in which a dose of drug should be ingested for a specified duration;

(g) **"Level I Prescribing Authority"** means the ability of a licensed pharmacist to prescribe drugs in the circumstances enumerated in sections 4, 5, 6, 7, 8, 9, 10 or 11 of this Part K;

(h) **"Level II Prescribing Authority"** means the ability of a licensed pharmacist to prescribe drugs in the circumstances enumerated in sections 12, 13, 14, 15, 16, 17 or 19 of this Part K;

(i) **"Pharmaceutical Information Program"** means Saskatchewan's centralized electronic registry of patient medication records, gathered pursuant to subsection 3.3(2) of *The Prescription Drugs Act*;

(j) **"Pharmacist Assessment Record"** means the clinical record completed, or caused to be completed, by one or more licensed pharmacists for the purpose of documenting the information described in subsection 3(2) of this Part K;

(k) **"Pharmacologic class"** is a group of drugs that share one of the three scientifically documented properties or attributes, depending on what is clinically meaningful: (1) mechanism of action, (2) physiologic effect, also known as "therapeutic effect", "therapeutic equivalence" or "clinical equivalence" and (3) chemical structure (CS);

(l) **"Practitioner"** for the purposes of this Part K, means a practitioner as defined in clause 2(i) of Part A of these bylaws, excluding a licensed pharmacist;

(m) **"Professional relationship"** means a relationship between a patient and a licensed pharmacist or practitioner in which a professional service is provided for the purpose of optimizing the patient's health or drug therapy;

(n) **"Public Health Care Institution"** means a designated facility as defined in *The Facility Designation Regulations* or the Saskatchewan Cancer Agency, continued pursuant to *The Cancer Agency Act*;

(o) **"Route of Administration"** means the primary routes of administration for dosage forms including parenteral, gastrointestinal, topical, mucosal and inhalation;

(p) **"Therapeutic substitution"** means substituting a prescribed drug for a drug that is within the same pharmacologic class and limited to the scientific properties defined in clause 1(k) of this Part K;

(q) All references to a section, subsection, clause, or subclause of these bylaws refers to the section, subsection, clause, or subclause in this Part K unless otherwise stated.

General Requirements for all Prescribing

2(1) A licensed pharmacist who exercises any prescribing authority pursuant to this Part K shall do so in accordance with the following requirements:

(a) the licensed pharmacist must have successfully completed the training, competency and practice requirements for the prescribing authority being exercised as stipulated by this Part K;

(b) prescribing shall only be done for patients with whom the licensed pharmacist has developed a professional relationship;

(c) for prescribing authority other than that stipulated in subsections 5(8), 10(1), 11(1), 13(1), 14(1), 15(1) or 19(1), the licensed pharmacist reasonably believes, after making inquiries that are reasonable in the circumstances, that there exists an active professional relationship between the practitioner and the patient;

(d) the licensed pharmacist must have the appropriate information to inform the prescribing decision;

(e) the licensed pharmacist must have reasonably satisfied themself that the prescribing decision is appropriate in the circumstances based on their assessment of the patient and that the prescribing decision is proper in the judgment of the licensed pharmacist;

(f) a licensed pharmacist must have reviewed the patient's medication history in the Pharmaceutical Information Program prior to prescribing a drug, unless the licensed pharmacist is unable to access the patient's medication history in the Pharmaceutical Information Program and is unable to make a record therein because the patient is not a resident of Saskatchewan, in which case the licensed pharmacist may prescribe a drug to the patient in accordance with these bylaws upon the making of inquiries, that are reasonable in the circumstances, into the patient's medication history;

(g) the licensed pharmacist must have a system in place to ensure patients receive appropriate follow-up care;

(h) the licensed pharmacist shall take appropriate follow-up action if the therapeutic results are outside of the expected, normal or reference range, which may include one or more of, but is not limited to:

(i) discussing the results with the patient or other members of the patient's health care team;

(ii) developing and implementing a plan for ongoing monitoring or management;

(iii) revising drug therapy, if authorized pursuant to Part K of these bylaws; or

(iv) recommending changes to drug therapy by another member of the patient's health care team;

(i) the licensed pharmacist must only prescribe a drug if the licensed pharmacist reasonably believes that the prescription decision of the licensed pharmacist has been consented to by the patient, in accordance with the following:

(i) in the context of services provided within a Public Health Care Institution, the licensed pharmacist reasonably believes that the prescription decision of the licensed pharmacist has been consented to in accordance with the bylaws or policies of the Public Health Care Institution regarding consent; or

(ii) in the context of a practice outside of a Public Health Care Institution, the licensed pharmacist reasonably believes, after the making of inquiries that are reasonable in the circumstances, that the prescription decision of the licensed pharmacist has been consented to:

(A) by the patient, if the licensed pharmacist has a reasonable basis to believe that the person has the capacity to make an informed health care decision;

(B) by a person appointed as the patient's personal guardian or the patient's co-decision maker pursuant to *The Adult Guardianship and Co-decision-making Act*;

(C) by the patient's parent or legal guardian, if the licensed pharmacist has a reasonable basis to believe that the person does not have the capacity to make an informed health care decision by reason of the patient's infancy; or

(D) by the patient's spouse, if the patient does not have the capacity to make an informed health care decision and no person has been appointed as the patient's co-decision maker or personal guardian;

(j) a licensed pharmacist who is prescribing a drug monitored by the Prescription Review Program, or other like provincial program, must do so in accordance with its applicable policies and procedures;

(k) the licensed pharmacist must not prescribe for themselves, family members, or for any person with whom they have a close personal relationship, except in emergency circumstances or when another appropriate health care professional is not readily available.

(2) Nothing in these bylaws permits a licensed pharmacist to delegate the licensed pharmacist's prescribing authority.

(3) If, in the opinion of the Registrar, extraordinary circumstances exist which demonstrate that it is in the public interest to do so, the Registrar may, according to the terms and conditions prescribed by Council, authorize licensed pharmacists to:

(a) prescribe a supply of a drug which exceeds the amount in subsection 5(2) or subsection 5(5) without the express authority of a practitioner;

(b) prescribe a drug without complying with subsections 5(1), 5(4) or clause 5(9)(d);

(c) prescribe a drug without complying with clause 2(1)(c);

(d) prescribe a drug without complying with subsection 3(3); or

(e) make a therapeutic substitution for a drug without complying with the practice, training, and competency requirements for Level II Prescribing Authority.

(4) The Registrar shall specify the limitations or restrictions on such authorization conferred pursuant to subsection 2(3).

Pharmacist Assessment Record

3(1) A licensed pharmacist who prescribes a drug pursuant to the authority of these bylaws must record, or cause to be recorded, a record of such prescription in a Pharmacist Assessment Record and may request a licensed pharmacy technician to assist in recording only the drug distribution information required by subsection 3(2).

(2) The Pharmacist Assessment Record for each drug prescribed under the authority of these bylaws must include:

(a) the date of the prescription;

(b) the name, address, birthdate, and provincial Health Services Number of the person for whose benefit the drug is given;

(c) the proper name, common name or brand name of the prescribed drug, and the quantity thereof;

(d) the drug's strength, where appropriate;

(e) the dosage regimen;

(f) the amount prescribed;

(g) the assessment of the licensed pharmacist, including relevant patient information, any drug-related problems, action plans, and explicit instructions for patient usage of the drug;

(h) the name of the prescribing licensed pharmacist; and

(i) the rationale of the prescribing licensed pharmacist for the prescription, including reference to the current peer-reviewed evidence-based resources or clinical practice guidelines used, when required by this Part K.

(3) Except when prescribing as provided in subsections 5(1), 5(4), section 6, 7 or 11, a licensed pharmacist who prescribes a drug under the authority of these bylaws, must provide, or cause to be provided, the Pharmacist Assessment Record associated with that prescription to the patient's primary practitioner and, where appropriate, other practitioners involved in the patient's care:

(a) immediately, if in the judgment of the licensed pharmacist, the practitioner immediately requires the record to provide safe care to the patient; or

(b) as soon as reasonably possible, in all other cases.

LEVEL I PRESCRIBING AUTHORITY

Training and Competency Requirements

4(1) A licensed pharmacist has Level I Prescribing Authority with respect to an individual patient if the licensed pharmacist has successfully completed the Level I Prescribing Authority training, competency and practice requirements, as stipulated in subsections 4(2), 4(4) and 4(7).

(2) The Level I Prescribing Authority training and competency requirements are:

(a) *Prescribing Authority Training:* successful completion of the approved prescribing authority Level I basics course offered by the University of Saskatchewan continuing professional development for pharmacy professionals program, or an equivalent course or alternative training requirement approved by Council;

(b) *Minor Ailments, Self-Care Training:* successful completion of the following requirements, except where the licensed pharmacist practices in an environment in which the licensed pharmacist will not provide self-care services or prescribe a drug which is indicated for self-care:

(i) the approved basics course for prescribing for minor ailments and self-care, offered by the University of Saskatchewan continuing professional development for pharmacy professionals program, or an equivalent course or alternative training requirement approved by Council;

(ii) additional minor ailments and self-care implementation and guidelines courses approved by Council; and

(c) successful completion of any additional training requirements approved by Council.

(3) The Level I Prescribing Authority requirements specified in subsection 4(2) of this Part K shall be reviewed and evaluated periodically by the Registrar, at timeframes agreed to by Council, and shall be amended periodically subject to the approval of Council.

Practice Requirements

(4) A licensed pharmacist may only exercise Level I Prescribing Authority with respect to an individual patient if a Collaborative Practice Environment exists between the licensed pharmacist and a practitioner who is responsible for the care of the individual patient.

(5) For the purposes of subsection 4(4), a Collaborative Practice Environment does not exist between a licensed pharmacist and a practitioner when:

(a) the practitioner has communicated to the licensed pharmacist in writing that no Collaborative Practice Environment exists, the nature of the concerns, and the individual patient or class of patients impacted; and

(b) the practitioner confirms that the patient or class of patients have been informed of the concerns with the pharmacist's prescribing and the potential impact on patient care.

(6) A Collaborative Practice Environment is presumed to exist with a Public Health Care Institution, in any circumstance where the patient care functions or drug therapy management services performed in, or through a Public Health Care Institution, are in accordance with the Collaborative Practice Agreement.

(7) A licensed pharmacist exercising Level I Prescribing Authority must adhere to any policies approved by Council with respect to exercising Level I Prescribing Authority.

Continuing Existing Prescriptions

5(1) A licensed pharmacist with Level I Prescribing Authority may prescribe an additional quantity of a drug previously prescribed to the patient by a practitioner if:

(a) requested to do so by the patient;

(b) the patient's medication history indicates chronic and stabilized use of the relevant drug; and

(c) the patient's remaining supply of the drug will not be sufficient for the patient to maintain the prescribed frequency and dosage amount until the date of their next appointment with a practitioner.

(2) A licensed pharmacist prescribing under subsection 5(1) is limited to a maximum of three month's duration.

(3) A licensed pharmacist prescribing under subsection 5(1) must not alter the dosage regimen or dosage amount of the prescription.

Unable to Access Supply

(4) In the event that the patient's supply of the drug is currently inaccessible to the patient due to distance or other reasons provided by the patient, a licensed pharmacist with Level I Prescribing Authority, if requested to do so by a patient, may prescribe an additional quantity of a drug previously prescribed to the patient by a practitioner if the patient's medication history indicates chronic and stabilized use of the drug.

(5) A licensed pharmacist prescribing pursuant to subsection 5(4):

(a) must limit the quantity to the amount necessary to meet the reasonable needs of the patient until such time as the patient, with the exercise of reasonable diligence, would be able to access their currently inaccessible supply; and

(b) must not alter the dosage amount or dosage regimen previously prescribed by the practitioner.

Back-to-Back Pharmacist Prescribing

(6) A licensed pharmacist is not permitted to prescribe a drug, pursuant to the authority of subsections 5(1) or 5(4), if the most previous prescription for that drug was issued by a licensed pharmacist, unless the pharmacist is prescribing as authorized by:

(a) subsection 6(1);

(b) subsection 7(1);

(c) subsection 11(1); or

(d) clause 12(1)(a), subclauses 12(1)(b)(iv) or 12(1)(b)(v) if it is prescribed in accordance with the applicable requirements in section 12, and the last prescription is indicated for the disease condition for which the authority is conferred.

Notification

(7) A licensed pharmacist who exercises prescribing authority pursuant to subsections 5(1) or 5(4) is not required to provide the Pharmacist Assessment Record to the patient's primary practitioner, pursuant to subsection 3(3), unless it is requested by a practitioner.

Emergency Situation

(8) Subject to the limitations of subsection 5(9), in an emergency situation, a licensed pharmacist with Level I Prescribing Authority may prescribe a quantity of drug sufficient to meet the reasonable needs of a patient until such time as the patient, with the exercise of reasonable diligence, would be able to consult a practitioner.

(9) A licensed pharmacist may only prescribe a drug pursuant to the authority conferred by subsection 5(8) if:

(a) the licensed pharmacist has assessed the patient's medication history, including, though not limited to, evaluating the patient's previous use of and current supply of the drug, and is satisfied that the patient is stabilized on the drug, regardless of the drug being used acutely, sporadically, or on an as-needed basis;

(b) the drug has been prescribed to the patient by a practitioner or has been properly dispensed to the patient under the authority of a prescription made by a practitioner;

(c) the licensed pharmacist has taken steps to ensure that the patient is in an emergency situation, which includes but is not limited to:

(i) a life-threatening situation; or

(ii) a situation where an interruption in drug therapy will result in serious or imminent harm to the patient's health or well-being; and

(d) the most previous prescription for the drug was not issued by a licensed pharmacist who is prescribing under the authorization of subsection 5(8).

(10) When a licensed pharmacist has Level I Prescribing Authority, their ability to prescribe drugs in emergency situations and to continue drug therapy management is not limited by:

(a) the drug being classified as a Schedule I drug;

(b) there being no recent diagnosis by a practitioner on which to base the new or continued prescription; or

(c) the patient no longer having an active professional relationship with a practitioner.

(11) If a drug is prescribed in emergency circumstances pursuant to subsection 5(8), the licensed pharmacist must provide an immediate referral of the patient to a practitioner and notify that practitioner of the drug provided.

Insufficient Information

6(1) If a prescription lacks legally necessary information without which the drug cannot be dispensed, a licensed pharmacist with Level I Prescribing Authority may insert the missing information, if the licensed pharmacist is satisfied that the prescribing practitioner's intent is clear and that the medically necessary information was unintentionally omitted.

(2) The licensed pharmacist inserting missing information pursuant to subsection 6(1) must promptly notify the prescribing practitioner of the information which was inserted and the drug which was dispensed.

Increasing Suitability of Drug Prescribed by a Practitioner

7(1) A licensed pharmacist with Level I Prescribing Authority may alter the dosage form of a drug which has been prescribed by a practitioner if the licensed pharmacist reasonably determines that another dosage form would be more beneficial to the patient.

(2) A licensed pharmacist altering the dosage form, as authorized pursuant to subsection 7(1), may only alter the dosage amount, dosage regimen, or quantity of a drug if it is required, as a result of the dosage form being altered, to maintain the equivalent course of treatment as intended by the original prescription.

(3) A licensed pharmacist altering the dosage form, as authorized pursuant to subsection 7(1), is only permitted to change the route of administration when the route of administration of the drug previously prescribed by the practitioner is not commercially available.

Enhancing Safety and Drug Effectiveness

8(1) A licensed pharmacist with Level I Prescribing Authority may alter the dosage amount or dosage regimen of a drug which has been prescribed by a practitioner, in the following situations:

(a) to prevent serious or imminent harm to the patient's health or well-being;

(b) to correct an obvious error in dosage amount or dosage regimen;

(c) to align with antimicrobial stewardship; or

(d) to align with opioid stewardship.

(2) Prescribing pursuant to subsection 8(1) must be in accordance with:

(a) current peer-reviewed evidence-based resources;

(b) clinical practice guidelines; or

(c) the drug product monograph.

(3) When a licensed pharmacist is prescribing pursuant to subsection 8(1), the quantity must not exceed the amount directed by the original prescription unless it is required to align with antimicrobial stewardship resources specified in subsection 8(2).

(4) The licensed pharmacist must notify the prescribing practitioner of the alteration in dosage amount or dosage regimen of a drug which was prescribed by the licensed pharmacist pursuant to subsection 8(1).

Drug Reconciliation

9(1) A licensed pharmacist with Level I Prescribing Authority may prescribe a drug for a patient if the patient:

(a) has been recently discharged from a hospital, licensed special-care home, or personal care home, without obtaining a continuing prescription for a drug which had been prescribed while the patient was in a hospital, licensed special-care home, or personal care home; or

(b) has been admitted to a hospital, licensed special-care home, or personal care home.

(2) A licensed pharmacist may only prescribe drugs pursuant to the authority conferred by subsection 9(1) if the pharmacist reasonably determines, after the making of inquires that are reasonable in the circumstances, that:

(a) the patient requires the drug so as not to suffer harm;

(b) there is no practitioner reasonably available to issue a prescription for the drug; and

(c) one of the following conditions is met:

(i) in the case of clause 9(1)(a), in the licensed pharmacist's judgment, the prescription for the drug was unintentionally omitted by the practitioner; or

(ii) in the case of clause 9(1)(b), subsequent to the patient being admitted to a hospital, licensed special-care home, or personal care home, it is determined by the licensed pharmacist that the patient ought to be receiving the drug.

(3) When a licensed pharmacist is prescribing pursuant to subsection 9(1), the quantity must not exceed a three months' supply of the drug.

Prescribing for Minor Ailments, Self-Care

10(1) A licensed pharmacist with Level I Prescribing Authority who has completed the training and competency requirements specified in clause 4(2)(b) may prescribe a drug for self-care if the drug is indicated for self-care according to the protocols approved by Council.

(2) A licensed pharmacist with Level I Prescribing Authority may only prescribe a drug pursuant to the authority conferred by subsection 10(1) if the licensed pharmacist reasonably determines, after the making of inquiries that are reasonable in the circumstances, that:

(a) the patient has performed a self-assessment and the self-assessment is reasonable; and

(b) the drug requested or indicated is appropriate for the treatment of the patient's self-assessed condition.

Administrative Prescribing

11(1) A licensed pharmacist with Level I Prescribing Authority who has completed the requirements specified in clause 4(2)(b) may prescribe a Schedule II, III or Unscheduled drug for administrative purposes in the following situations:

(a) to obtain third-party drug coverage; or

(b) to support drug formulary management initiatives of the Ministry of Health.

(2) For the purposes of subsection 11(1), a licensed pharmacist may only initiate an original prescription for a Schedule II, III or Unscheduled drug if it is within their scope of practice to identify the initial need for the drug.

(3) When a licensed pharmacist initiates a prescription as authorized pursuant to subsection 11(2), they must:

(a) follow reputable clinical tools, based on the best available evidence and expert reviews; and

(b) be in accordance with the Standards of Practice approved by Council.

(4) Section 11 does not permit a licensed pharmacist to identify the initial need for a drug or initiate the prescription for diseases that are not within the licensed pharmacist's scope of practice to identify or initiate.

LEVEL II PRESCRIBING AUTHORITY

Training and Competency Requirements

12(1) A licensed pharmacist is authorized to prescribe under Level II Prescribing Authority with respect to an individual patient:

(a) as provided for in a Collaborative Practice Agreement, if the licensed pharmacist has successfully completed the practice, training and competency requirements as stipulated in subsections 12(2), 12(5), as required by the Collaborative Practice Agreement; or

(b) with respect to any specialty area listed below, if the licensed pharmacist has successfully completed the practice, training and competency requirements stipulated in subsections 12(2), 12(3) and 12(5):

(i) Vaccine Preventable Diseases in Canada;

(ii) Travel Health "A";

(iii) Travel Health "B";

(iv) Advanced Prescribing "A";

(v) Advanced Prescribing "B"; or

(vi) Other Diseases Identified by the Minister of Health or Designate.

(2) A licensed pharmacist may not exercise Level II Prescribing Authority unless the licensed pharmacist has successfully completed the Level I Prescribing Authority requirements as described in subsections 4(1) and 4(2), and any other training requirements as determined by Council.

(3) The Level II Prescribing Authority specialty area training and competency requirements shall include, without limitation:

(a) *Vaccine Preventable Diseases in Canada:* the training and competency requirements approved by Council for prescribing authorized pursuant to section 13 including, without limitation:

(i) successful completion of Advanced Method Certification as stipulated in section 5 of Part L; and

(ii) successful completion of the vaccine preventable disease in Canada course offered by the University of Saskatchewan continuing professional development for pharmacy professionals program, or an equivalent course or alternative training requirement approved by Council;

(b) *Travel Health "A":* the training and competency requirements approved by Council for prescribing authorized pursuant to section 14 including, without limitation:

(i) successful completion of the requirements stipulated in clause 12(3)(a);

(ii) successful completion of the travel health specialty course offered by the University of Saskatchewan continuing professional development for pharmacy professionals program, or an equivalent course or alternative training requirement approved by Council; and

(iii) successful completion of a comprehensive travel medicine course as determined by Council;

(c) *Travel Health "B":* the training and competency requirements approved by Council for prescribing authorized pursuant to section 15 including, without limitation:

(i) successful completion of the requirements stipulated in clause 12(3)(a);

(ii) successful completion of the travel health specialty course offered by the University of Saskatchewan continuing professional development for pharmacy professionals program, or an equivalent course or alternative training requirement approved by Council; and

(iii) successful completion of the International Society of Travel Medicine (ISTM) Certification in Travel Health, or an equivalent certification or alternative training requirement approved by Council;

(d) *Advanced Prescribing "A":* the training and competency requirements for prescribing authorized pursuant to section 16 including, without limitation:

(i) successful completion of the prescribing authority advanced prescribing "A" course offered by the University of Saskatchewan continuing professional development for pharmacy professionals program or an equivalent course or alternative training requirement approved by Council; and

(ii) any other training and competency requirements approved by Council;

(e) *Advanced Prescribing "B":* the training and competency requirements for prescribing authorized pursuant to section 17 including, without limitation:

(i) certification or credential from a program widely accepted by credible sources in Canada or any other equivalent training and competency requirements approved by Council;

(ii) successful completion of an accredited prescribing authority advanced "B" course offered by the University of Saskatchewan continuing professional development for pharmacy professionals program or an equivalent course or alternative training requirement approved by Council; and

(iii) any other training and competency requirements determined by Council;

(f) *Other Diseases Identified by the Minister of Health or Designate*, for prescribing authorized pursuant to section 19, the training and competency requirements shall be determined by:

(i) the Minister of Health or designate; and

(ii) the Registrar as approved by Council.

(4) The Level II Prescribing Authority requirements specified in subsections 12(2) and 12(3) shall be reviewed and evaluated periodically by the Registrar, at timeframes agreed to by Council, and shall be amended periodically subject to the approval of Council.

Practice Requirements

(5) With the exception of licensed pharmacists who are prescribing according to a Collaborative Practice Agreement in a Public Health Care Institution pursuant to clause 12(1)(a), a licensed pharmacist who exercises Level II Prescribing Authority must be competent in and use current peer-reviewed evidence-based resources or clinical practice guidelines pertaining to the condition being treated to determine appropriate drug choice.

(6) A licensed pharmacist who exercises Level II Prescribing Authority for one or more of the specialty areas listed in clause 12(1)(b) shall:

(a) ensure collaboration with the health care system as required by Council;

(b) adhere to the policies for Level II Prescribing as approved by Council; and

(c) successfully complete any additional training and meet competency standards as required by Council.

Collaborative Practice Agreements

(7) A Collaborative Practice Agreement for the purposes of clause 12(1)(a) must:

(a) be in writing and:

(i) in the case of an agreement as defined in clause 1(a)(i), be signed by each practitioner and licensed pharmacist who is a party to the Collaborative Practice Agreement; or

(ii) in the case of a bylaw or policy of a Public Health Care Institution, or agreement between one or more licensed pharmacists and a Public Health Care Institution as defined in subclause 1(a)(ii), be made or entered into by such institution in accordance with the applicable authority for making bylaws, policies or agreements, as the case may be;

(b) describe the authority of the licensed pharmacist to prescribe drugs within the scope of practice as authorized by Council, in accordance with the bylaws;

(c) confirm the existence of a Collaborative Practice Environment; and

(d) not interfere with a licensed pharmacist's ability to practice according to these bylaws and the policies, standards, or guidelines approved by Council.

(8) For the purposes of subsection 12(7), a Collaborative Practice Agreement may stipulate:

(a) conditions, limitations, or qualifications to the authority of a licensed pharmacist to exercise Level II Prescribing Authority including, without limitation:

(i) the ability to prescribe an appropriate drug to the patient, after the practitioner has provided a diagnosis of the patient, and to adjust the dosage regimen or dosage form, as required;

(ii) the ability to make one or subsequent therapeutic substitutions of drugs, if such therapeutic substitutions are in accordance with clinical practice guidelines or resources pursuant to subsection 12(5) and are proper in the judgment of the licensed pharmacist; and

(iii) the ability to alter the dosage amount or dosage regimen of drugs prescribed by the practitioner, if such alteration is proper in the judgment of the licensed pharmacist;

(b) that the authority of a licensed pharmacist to exercise Level II Prescribing Authority is dependent upon the presence or absence of circumstances that are stipulated, defined, or described in the Collaborative Practice Agreement, which circumstances may include:

(i) the urgency of the situation;

(ii) the disease state or condition;

(iii) the applicable patient groups;

(iv) the drug that is to be prescribed;

(v) the specialized training of the licensed pharmacist; or

(vi) any other circumstances to which the parties to the Collaborative Practice Agreement may agree.

Prescribing for Vaccine Preventable Diseases in Canada

13(1) A licensed pharmacist who has achieved the requirements specified in subclause 12(1)(b)(i) and clause 12(3)(a) may only prescribe vaccines for the prevention of the following diseases:

(a) Diphtheria;

(b) Haemophilus influenza Type B;

(c) Hepatitis A;

(d) Hepatitis B;

(e) Herpes zoster (Shingles);

(f) Human Papillomavirus (HPV);

(g) Measles;

(h) Meningococcal disease;

(i) Mumps;

(j) Pertussis;

(k) Pneumococcal disease;

(l) Polio;

(m) Rubella;

(n) Seasonal Influenza;

(o) Tetanus; and

(p) Varicella zoster (chickenpox).

(2) Where a licensed pharmacist prescribes a vaccine for a disease listed in subsection 13(1), which is indicated by the patient for travel outside of Canada, the licensed pharmacist must adhere to the requirements for the diseases listed in the Travel Health "A" category pursuant to section 14.

Prescribing for Travel Health "A"

14(1) A licensed pharmacist who has achieved the requirements specified in subclause 12(1)(b)(ii), clauses 12(3)(a) and 12(3)(b) may only prescribe vaccines or drug products with a travel indication for the prevention of the diseases listed below:

(a) Diseases listed in subsection 13(1);

(b) Cholera (pharmacist may prescribe the oral, inactivated vaccine only); and

(c) Traveler's diarrhea (pharmacist may prescribe prophylactic or pre-emptive treatment such as the oral, inactivated vaccine or antibiotics according to Council approved protocols).

Prescribing for Travel Health "B"

15(1) A licensed pharmacist who has achieved the requirements specified in subclause 12(1)(b)(iii), clauses 12(3)(a) and 12(3)(c) may only prescribe vaccines or drug products with a travel indication for the prevention of the diseases listed below:

(a) Diseases listed in subsection 13(1) and 14(1);

(b) Cholera (except the oral, inactivated vaccine);

(c) European Tick-Borne Encephalitis;

(d) Japanese Encephalitis;

(e) Rabies;

(f) Typhoid;

(g) Malaria;

(h) Altitude Illness; and

(i) Yellow Fever.

Advanced Prescribing "A" Therapeutic Substitution for a Practitioner-Initiated Prescription

16 After a practitioner has provided a diagnosis and issued a prescription for the patient, a licensed pharmacist who has achieved the requirements specified in subclause 12(1)(b)(iv) and clause 12(3)(d) may make one or subsequent therapeutic substitutions of drugs within the pharmacologic class approved by Council.

Advanced Prescribing "B" Initiating Drugs when Practitioner Diagnosis is Provided

17(1) After a practitioner has provided a diagnosis, a licensed pharmacist who has achieved the requirements specified in subclause 12(1)(b)(v) and clause 12(3)(e) may perform the following practices for chronic and other diseases approved by Council:

(a) initiate an appropriate drug and adjust the dosage amount, dosage regimen, or dosage form as required;

(b) make one or more subsequent therapeutic substitutions of drugs within the pharmacologic class approved by Council;

(c) alter the dosage amount or dosage regimen of drugs prescribed by a practitioner; or

(d) de-prescribe a drug if it is proper in the judgement of the licensed pharmacist.

Medical Records for Advanced Prescribing "B"

18(1) In accordance with *The Health Information Protection Act* and other applicable privacy legislation, a licensed pharmacist who prescribes a drug pursuant to the authority conferred by section 17 must keep a record of each patient contact that meets the following requirements:

(a) the record must be personally completed by the licensed pharmacist who is prescribing under this authority;

(b) the record must be legibly written or typewritten and state:

(i) the date that the licensed pharmacist saw the patient;

(ii) a record of the diagnosis provided by the patient's practitioner;

(iii) the licensed pharmacist's assessment of the patient, which includes the history obtained and the investigations ordered (when applicable); and

(iv) a record of the disposition of the patient, including the treatment provided or prescriptions written by the licensed pharmacist, professional advice given and particulars of any referral that is made by the licensed pharmacist to a practitioner;

(c) the patient record must include every report received respecting a patient from other health professionals where appropriate;

(d) the records are to be in the English language and kept in a systematic manner;

(e) the records must be completed in a timely manner and retrievable;

(f) the records may be made and maintained in an electronic computer system, provided:

(i) the system provides a visual display of the recorded information;

(ii) the system provides a means of access to the record of each patient by the patient's name and if the person has a provincial Health Services Number, by the health number;

(iii) the system is capable of printing the recorded information promptly;

(iv) the system is capable of visually displaying the recorded information for each patient in chronological order;

(v) the system maintains an audit trail that:

(A) records the date and time of each entry of information for each patient;

(B) indicates any changes in the recorded information;

(C) preserves the original content of the recorded information when changed or updated; and

(D) is capable of being printed separately from the recorded information of each patient;

(vi) the system includes a password or otherwise provides reasonable protection against unauthorized access; and

(vii) the system backs up files and allows the recovery of backed up files or otherwise provides reasonable protection against loss of, damage to and inaccessibility of information;

(g) a licensed pharmacist shall retain the records required by subsection 18(1) for:

(i) 10 years after the date of the last entry in the record; or

(ii) patients who are considered minors, until two years past the age of majority in Saskatchewan or 10 years after the date of the last entry in the record, whichever is the later date;

(h) for the purpose of clause 18(1)(g), the "last entry in the record" means the last entry or document received by the licensed pharmacist, which relates to the care provided by the licensed pharmacist;

(i) clause 18(1)(g) applies to living and deceased patients;

(j) a licensed pharmacist who ceases to practice shall:

(i) transfer the records to a licensed pharmacist with the same address and telephone number; or

(ii) transfer the records to:

(A) another licensed pharmacist practising in the locality;

(B) a medical records department of a health care facility; or

(C) a secure storage area with a person designated to allow health professionals and patients reasonable access to the records, as appropriate;

(k) a licensed pharmacist who ceases to practice shall notify patients when the transfer of records will take place at least 90 days in advance of the transfer, or, if it is unexpected, as soon as reasonably possible by at least one of the following methods:

(i) directly through one or more channels including letter-mail, email, telephone, or in person at scheduled appointments; or

(ii) indirectly, where direct notification is not reasonably possible, through one or more channels including posted notices, notices on website, media advisories or advertisements that are publicly accessible and displayed for a minimum of 90 days.

Prescribing for Other Diseases Identified by the Minister of Health or Designate

19(1) A licensed pharmacist who has achieved the requirements specified in subclause 12(1)(b)(vi) and clause 12(3)(f) may prescribe vaccines or drug products for the prevention or treatment of any diseases identified by the Minister of Health or designate**".**

(2) That PART M – PHARMACIST AUTHORITY: AUTHORIZED TESTS AND PRESCRIBED MEDICAL DEVICES be repealed and replaced with the following:

PART M - PHARMACIST AUTHORITY: AUTHORIZED TESTS AND PRESCRIBED MEDICAL DEVICES

Definitions

1 In this part:

(a) **"Access"** refers to pharmacists "looking up" test results from medical laboratory tests or patient-administered automated tests as approved by Council criteria and subject to privacy requirements for personal health information in Saskatchewan;

(b) **"Drug therapy management"** means patient-centered care provided through collaboration with patients and their health care teams to optimize safe, effective, and appropriate drug therapy, and includes preventing, identifying, and resolving drug related problems;

(c) **"Interpret"** means understanding and explaining the meaning of references, ranges (intervals), critical values, and detection limits of each technique;

(d) **"Medical Laboratory"** *The Medical Laboratory Licensing Act*, clause 2(f), defines a "medical laboratory" as a place where a test is performed or where a specimen is taken or collected for the purpose of transporting it to another medical laboratory where it is to be tested, unless it is exempted in *The Medical Laboratory Licensing Regulations*;

(e) **"Order"** means issuing a laboratory requisition to an individual or medical laboratory to obtain a specified laboratory test, for the purpose of delivering pharmacy or other health related services;

(f) **"Patient-Administered Automated Test"** refers to a test that is designed for patient self-use outside of a conventional laboratory or health care facility, without the assistance or supervision of a health care provider to yield a result, and which must be approved by Health Canada for "self-testing" or for personal or home use by the general public, independent of the assistance or supervision of a health care worker;

(g) **"Perform"** means the series of steps executed to obtain a test result, which includes the collection, handling, transportation, documentation, and storage of specimens, as well as performing the analytical techniques on specimens to obtain the result. May also be referred to as "conducting" or "administering" a test, or "testing";

(h) **"Point-of-Care Testing"** refers to analytical patient testing activities performed outside the physical facilities of a clinical laboratory, by an approved health care professional, using a wide variety of test kits and medical devices approved by Health Canada for sample collection and testing in a near-patient environment;

(i) **"Prophylaxis"** refers to measures taken to maintain or preserve health or to prevent disease, especially by specified means or against a specified disease;

(j) **"Screening"** refers to identifying the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms, which may include individuals with pre-symptomatic or unrecognized symptomatic disease;

(k) **"Specimen Collection"** refers to the process of obtaining specimens from the body for the purpose of administering a laboratory or point-of-care test through a variety of methods, including nasal swab, throat swab, saliva sample, blood draw, nasopharyngeal and other methods;

(l) **"Test"** means the examination or analysis of a specimen taken or collected from a human body to obtain information for screening, prophylaxis, treatment, or any other health-related purpose, which includes tests requiring the collection of a specimen to be analyzed at an accredited medical laboratory by a licensed medical laboratory technologist or through point-of-care testing, to obtain a result to inform a medical intervention;

(m) **"Use"** means using or interpreting the results of a Health Canada approved testing device or medical laboratory tests to inform a clinical decision in accordance with Parts J, K, L and M of these bylaws.

General Authorization

2 A licensed pharmacist may:

(a) access one or more of the medical laboratory tests approved by Council, if the medical laboratory test is indicated to assist with the screening or prophylaxis for a condition or disease or, management of drug therapy for a patient;

(b) use or interpret the results of one or more of the medical laboratory tests approved by Council if the medical laboratory test is indicated to assist with the screening or prophylaxis for a condition or disease, or management of drug therapy for a patient;

(c) order or perform medical laboratory tests approved by Council if the medical laboratory test is indicated to assist with the screening or prophylaxis for a condition or disease, or management of drug therapy for a patient, is authorized under a medical laboratory licence issued pursuant to *The Medical Laboratory Licensing Act, 1994*, and is in accordance with the practice, training and competency requirements approved by the Minister of Health and policies approved by Council;

(d) access, use, and interpret the results of patient-administered automated tests approved by Council; and

(e) prescribe treatments and devices approved by Council, which are related to the practice of pharmacy in Saskatchewan.

Preliminary Requirements and Follow-up Care

3 Licensed pharmacists who perform any of the functions listed under section 2 of this Part M shall do so in accordance with the following requirements:

(a) medical laboratory tests shall only be accessed for patients with whom the licensed pharmacist has developed a professional relationship;

(b) if a licensed pharmacist accesses a medical laboratory test, they must have a system in place to ensure the appropriate follow-up care;

(c) a licensed pharmacist who accesses a medical laboratory test shall take appropriate follow-up action if the results of the medical laboratory test are outside of the expected, normal, or reference range. Appropriate action may include, but is not limited to:

(i) discussing the results with the patient and/or other members of the patient's health care team;

(ii) developing and implementing a plan for ongoing monitoring or management;

(iii) initiating or revising drug therapy, if authorized within a Collaborative Practice Agreement pursuant to section 12 of Part K of these bylaws, or recommending changes to drug therapy to another member of the patient's health care team;

(iv) consulting with clinical/medical laboratory staff regarding unexpected or unusual results; or

(v) initiating or revising drug therapy as authorized pursuant to sections 16, 17, or 19 of Part K of these bylaws, where applicable;

(d) in the case that a licensed pharmacist receives a request from a patient regarding a medical laboratory test:

(i) the licensed pharmacist may provide the patient with the results of the medical laboratory test if deemed appropriate in the licensed pharmacist's professional opinion and in accordance with *The Health Information Protection Act*; however

(ii) the licensed pharmacist is not permitted to provide an interpretation of the results of the medical laboratory test unless it pertains to the pharmacist service being provided by the licensed pharmacist.

Exception for Licensed Pharmacists Practising in Public Health Care Institutions

4 This Part does not apply to licensed pharmacists practising in public health care institutions as defined in clause 1(n) of Part K of these bylaws and including the Saskatchewan Cancer Agency where the authority of the licensed pharmacist to access, order, perform, interpret, and use medical laboratory tests is governed by policies of the institution within which the licensed pharmacist is practising.

Emergency Authorization

5(1) Notwithstanding any other provision in this Part M or any other provision in the Act or these bylaws, if in the opinion of the Registrar extraordinary circumstances exist which demonstrate that it is in the public interest to do so, the Registrar may authorize:

(a) any licensed pharmacist to access, use, interpret or provide to patients the results of one or more of the medical laboratory tests approved by Council for use only in extraordinary circumstances:

(i) for purposes other than assisting with the management of drug therapy for a patient;

(ii) for purposes other than pharmacist services being provided by the licensed pharmacist; or

(iii) for patients where a professional relationship does not exist;

(b) any licensed pharmacist to perform one or more of the medical laboratory tests approved by Council for use only in extraordinary circumstances when the medical laboratory test:

(i) may not be indicated to assist with the management of drug therapy for a patient;

(ii) may be for purposes other than pharmacist services being provided by the licensed pharmacist;

(iii) is for patients where a professional relationship does not exist; and

(iv) is authorized pursuant to *The Medical Laboratory Licensing Act, 1994*, *The Medical Laboratory Licensing Regulations, 1995* and other provincial legislation, under the terms and conditions as specified.

(2) The licensed pharmacist performing medical laboratory tests and accessing, using, interpreting, and providing to patients the results of these tests must meet the competency and training requirements as specified by the Registrar and/or the provincial health authority as defined in subclause 2(x)(ii) of the Act.

(3) A licensed pharmacist who accesses a test result pursuant to clause 5(1)(a) or who performs any of the tests pursuant to clause 5(1)(b) of this Part M must have a system in place to ensure appropriate follow-up care, and shall take appropriate follow-up action as required by:

(a) the Registrar and in accordance with the policies approved by Council;

(b) the provincial health authority as defined in subclause 2(x)(ii) of the Act; and

(c) any other applicable officials including, without limitation, the Chief Medical Health Officer or designate.

(4) For the purposes of clauses 5(1)(a) and (b) of this Part M:

(a) the test results accessed, used, interpreted, and provided to patients may be derived from any testing modality authorized by Health Canada, including:

(i) those performed in a licensed medical laboratory by licensed laboratory-trained personnel;

(ii) analytical patient testing activities performed at point-of-care or outside the physical facilities of a clinical laboratory by an operator who may or may not be laboratory-trained personnel; or

(iii) any other testing modality approved by Council;

(b) the tests performed may be any testing modality and must:

(i) be approved by Health Canada;

(ii) meet the requirements pursuant to *The Medical Laboratory Licensing Act, 1994* and *The Medical Laboratory Licensing Regulations, 1995*; and

(iii) be approved by Council for use only in extraordinary circumstances;

(c) the tests may be indicated for purposes other than to assist with the management of drug therapy for a patient.

(5) Notwithstanding any other provision in section 2 or 3 of this Part M or any other provision in the Act or these bylaws, the Registrar shall specify the terms, limitations, restrictions, or conditions on such authorization conferred pursuant to subsections 5(1), (2), (3), and (4) of this Part M.

CERTIFIED TRUE COPY:

Jeana Wendel, Registrar,
Saskatchewan College of Pharmacy Professionals.
Date: April 21, 2023.

APPROVED BY:

Honourable Paul Merriman,
Minister of Health.
Date: July 18, 2023.

The Provincial Court Act, 1998

[*section 18*]

LIST OF TEMPORARY JUDGES – PROVINCIAL COURT OF SASKATCHEWAN

July 31, 2023

Notice is hereby given that, effective July 31, 2023, Judge Donna C. Scott is added to the list of persons eligible to be appointed as temporary judges of the Provincial Court of Saskatchewan.

RULES OF COURT/RÈGLES DE PROCÉDURE

COURT OF KING'S BENCH FOR SASKATCHEWAN

(Practice Directives)

GOWNING POLICY FOR COUNSEL

Effective: July 17, 2023

Revised: Practice Directive GA-PD NO. 5 issued May 1, 2020, is repealed and replaced with this revised Practice Directive GA-PD NO. 5 effective July 17, 2023

REFERENCE: GA-PD NO. 5

Information Note

Gowning is part of our legal heritage. It reminds lawyers of their special privilege to represent parties before His Majesty's superior courts. It is also a uniform that removes visual distinction between counsel and symbolically places all counsel on the same level at the Bar, excepting only the distinction between barrister and King's Counsel robes. Proper attire and wearing that attire in a proper manner is a mark of professionalism.

Unless the presiding judge otherwise directs:

1 Counsel are required to gown for all appearances before the Court of King's Bench, except for the appearances described in paragraph 2.

2 Counsel are not required to gown for:

(a) chambers;

(b) pre-trial conferences;

(c) *The Residential Tenancies Act, 2006* appeals heard in chambers;

(d) bail reviews; and

(e) in detention review chambers under s.525 of the *Criminal Code*.

3 Gowning means court shirt, court vest, tabs and robe, without additional adornment. Dress pants or skirts are black, charcoal gray or morning stripe. Shoes or pumps are black.

4 King's Counsel robes, vest and tabs are to be worn only by the barristers so appointed.

5 Counsel may modify their traditional court attire in order to accommodate their personal circumstances. Counsel wearing altered attire are requested to advise the court clerk or the local registrar in advance of the appearance to ensure that they do not need to discuss their personal circumstances or modified attire on the record or in open court.

Chief Justice M.D. Popescul
Court of King's Bench for Saskatchewan.

Illustration

NOTICES OF SALE AND AUCTION/AVIS DES VENTES AUX ENCHÈRES

The Commercial Liens Act

NOTICES OF SALE AND AUCTION – ASTRO TOWING

Notice is hereby given that *Astro Towing*, carrying on business at 126 Gladstone Cres., Saskatoon SK S7L 3R6, has seized and is disposing of the following described vehicles under the terms and conditions of *The Commercial Liens Act* and *The Personal Property Security Act, 1993*:

One 2010 Honda Accord EX-L
Serial No. 1HGCS2B80AA800543
Registered Owner: Joe Ahpay

One 2015 Chrysler 300S
Serial No. 2C3CCAGG2FH830730
Registered Owner: Travis Pritchard

One 2018 Ford Ecosport S
Serial No. MAJ3P1RE0JC238398
Registered Owner: Charles Neil-Curley

One 2003 GMC Yukon
Serial No. 1GKEK13Z23J198809
Registered Owner: Tyler Wegner

The vehicles will be available for viewing or private sale at *PBR Auctions* compound located 105-71st St. W, Saskatoon SK S7R 1B4, on or after July 31st, 2023.

The registered owners of the vehicles have first rights to these vehicles after all fees and expenses incurred have been paid in full. Please contact Raelene Purdy of *Astro Towing* at 306-242-2030 if you are interested.

Notice is hereby given that *Astro Towing*, carrying on business at 126 Gladstone Cres., Saskatoon SK S7L 3R6, has seized and is disposing of the following described vehicles under the terms and conditions of *The Commercial Liens Act* and *The Personal Property Security Act, 1993*:

One 2008 Dodge Ram 2500 Quad
Serial No. 3D7KS28D58G157557
Registered Owner: Jerilee Okemaysim

One 2007 Chrysler Pacifica Touring
Serial No. 2A8GM68X27R109057
Registered Owner: Braden Lavel

One 2005 Ford F-150
Serial No. 1FTPX14595FA70249
Registered Owner: Ronald McNarland

The vehicles will be available for viewing or private sale at *PBR Auctions* compound located 105-71st St. W, Saskatoon SK S7R 1B4, on or after August 7th, 2023.

The registered owners of the vehicles have first rights to these vehicles after all fees and expenses incurred have been paid in full. Please contact Raelene Purdy of *Astro Towing* at 306-242-2030 if you are interested.

Dated this 28th day of July, 2023.

Raelene Purdy,
Astro Towing.

NOTICE TO ADVERTISERS

PLEASE NOTE: The deadline for submissions to *The Saskatchewan Gazette* is 5 p.m. on the Friday preceding the week of publication. If a holiday occurs within the week of publication, the deadline is set back to 5 p.m. of the previous Thursday. Please allow yourself at least one full week to ensure mail delivery of Gazette submissions. Publication of any material received late will be delayed until the following week's issue.

All material for publication in *The Saskatchewan Gazette* must be submitted electronically (MS Word or WordPerfect) accompanied by a signed hard copy to the Office of the King's Printer, Ministry of Justice, B19-3085 Albert St., Regina SK S4S 0B1, tel. (306)787-6948, or by E-mail: **gazette@gov.sk.ca**.

Each document or disk must be complete in the form required for publication and must be separate from the covering letter. Signatures on all documents must be typewritten or clearly printed immediately below the written signatures.

Prepayment is required for ALL notices placed in *The Saskatchewan Gazette* by non-government clients. Cheques or money orders must be made payable to the Minister of Finance. Please include the GST in addition to regular charges at the rate of 5% each for those items listed below under "GST Payable".

The minimum charge for publication of notices not specified below is $16.00 for each notice, which sum shall accompany the material when forwarded for publication.

The following are minimum rates for advertising in *The Saskatchewan Gazette*:

GST Payable

Notices under *The Saskatchewan Insurance Act*	Two issues	$35.00
Notice of Intention to Apply for a Private Bill	Two issues	40.00
Notice of Sale and Auction	One issue	30.00*
Notice of Sale of Unclaimed Shipments	One issue	20.00
Notices under *The Tax Enforcement Act*	Five parcels or less, for a minimum charge of	20.00
	(Additional parcels are $0.75 each; metes and bounds descriptions are $3.50 each)	

GST Exempt

Notices under *The Companies Winding Up Act*	Two issues	$35.00
Notices under *The Traffic Safety Act** or *The Commercial Liens Act* (Vehicle Auctions)	One issue	$20.00

*Please note that Auctioneers acting pursuant to *The Traffic Safety Act* must be licensed under *The Auctioneers Act*.

Notices re: Assessment Rolls (Municipal)	One issue	$30.00

One copy of your submission as it appeared in *The Saskatchewan Gazette* is mailed to government advertisers who are invoiced. With prepayment, a copy of your submission is available on request from the Office of the King's Printer.

Subscriptions

Yearly subscription rate to *The Saskatchewan Gazette* (Paper Copy)	Payable in advance	$125.00
Shipping charge per issue		$5.00

AVIS AUX ANNONCEURS

SACHEZ QUE: La date de tombée pour les soumissions à la *Gazette de la Saskatchewan* est le vendredi à 5 p.m., précédant la semaine de la parution. En cas de jour férié à l'intérieur de la semaine de parution, la date de tombée sera remise un jour avant, soit le jeudi à 5 p.m. Pour les envois de soumissions à la Gazette par la poste, veuillez prévoir une semaine au complet. La parution de tout matériel reçu en retard sera remise au numéro de la semaine suivante.

Tous les documents qui paraîtront dans la *Gazette de la Saskatchewan* doivent être soumis électroniquement (MS Word ou WordPerfect) et accompagnés d'une copie papier signée et envoyée au bureau de l'Imprimeur du Roi, ministère de la Justice de la Saskatchewan, B19-3085, rue Albert, Regina SK S4S 0B1, tél. 306-787-6948, ou par courriel: **gazette@gov.sk.ca.**

Chaque document ou disquette doit être complet, conformément aux normes de parution, et doit être séparé de la lettre d'accompagnement. Les signatures sur les documents doivent être dactylographiées ou écrites lisiblement en lettres moulées et doivent apparaître immédiatement en dessous de la signature écrite.

Le paiement d'avance est exigé pour TOUS les avis placés dans la *Gazette de la Saskatchewan* par les clients non gouvernementaux. Les chèques ou les mandats doivent être établis à l'ordre du ministère des finances de la Saskatchewan. Veuillez y inclure la TPS en plus des tarifs réguliers au taux de 5 % pour chaque article cité ci-dessous dans la catégorie « soumis à la TPS ».

Le prix minimal pour la parution d'avis non inclus dans la liste ci-dessous, est de 16 $ par avis. Le paiement devra accompagner le matériel envoyé aux fins de parution.

Voici les tarifs minimum pour les publications d'annonces dans la *Gazette de la Saskatchewan*:

Soumis à la TPS

Avis en vertu de la *Saskatchewan Insurance Act*	Deux numéros	35$
Avis d'intention de demander l'adoption d'un projet de loi d'intérêt privé	Deux numéros	40$
Avis de vente aux enchères	Un numéro	30$
Avis de vente de marchandises non réclamées	Un numéro	20$
Avis en vertu de la *Tax Enforcement Act*	Cinq parcelles ou moins, pour un prix minimal de (Les parcelles supplémentaires sont au prix de 0,75 $ chacune; les descriptions par mesurage et délimitation coûtent 3,50$ chacune.)	20$

Exempts de TPS

Avis en vertu de la *Companies Winding Up Act*	Deux numéros	35$
Avis en vertu de la *Traffic Safety Act** or *ou Loi sur les privilèges à base commerciale*(Encans de véhicules)	Un numéro	20$

*Veuillez noter que les encanteurs qui agissent en vertu de la *Traffic Safety Act* doivent détenir une licence conformément à la *Auctioneers Act*.

Avis au sujet du rôle d'évaluation (Municipal)	Un numéro	30$

Un exemplaire de votre soumission, telle que parue dans la *Gazette de la Saskatchewan*, est envoyé aux gouvernements qui ont placé une annonce facturée. Si vous payez à l'avance, un exemplaire de votre soumission est disponible sur demande auprès du bureau de l'Imprimeur du Roi.

Abonnement

Tarif d'abonnement annuel à la *Gazette de la Saskatchewan* (copie papier)	Payable à l'avance	125$
Frais de livraison par numéro		5$

FOR INFORMATION CONTACT THE OFFICE OF THE KING'S PRINTER AT/ POUR OBTENIR DES RENSEIGNEMENTS, COMMUNIQUEZ AVEC LE BUREAU DE L'IMPRIMEUR DU ROI AU:

Name/Nom	Title/Titre:	Telephone/ Téléphone
Marilyn Lustig-McEwen	King's Printer	(306) 787-9345
Duane Alan Cook	Senior Legislative Editor	(306) 787-9062
Kris Stratton	Legislative Editor	(306) 787-9151
Carla Windl	Gazette Designer	(306) 787-6948
Charlotte Matisz	Acts & Publications Orders, Accounts Receivable	(306) 787-6894

. . . or call toll free in Saskatchewan 1-800-226-7302/
ou en Saskatchewan, composez sans frais le 1-800-226-7302

The Office of the King's Printer counter service is 8 am to noon, 1 to 5 pm, Monday to Friday. Please ring doorbell for service.

Should you require a publication for pick up or have a delivery for our office, please call 306-787-6894, toll free in Saskatchewan 1-800-226-7302 or email publications@gov.sk.ca and a staff member will assist you.

Thank you for your continued patronage.

Les heures d'ouverture du service au comptoir de l'Imprimeur du Roi sont du lundi au vendredi, de 8 h à midi et de 13 h à 17 h. Veuillez sonner à la porte pour être servi.

Pour ramasser une publication ou effectuer une livraison à notre bureau, veuillez composer le 306-787-6894, ou le 1-800-226-7302 sans frais en Saskatchewan ou encore envoyer un courriel à publications@gov.sk.ca et un membre du personnel vous aidera.

Nous vous remercions de continuer d'utiliser nos services.

Printed under the authority of the Office of the King's Printer/
Imprimé sous l'Autorité de l'Imprimeur du Roi pour la Saskatchewan
Regina (Saskatchewan) ©2023